| 國立成功大學 |
2023 |
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
|
Lim, Y.-S.;Chan, H.L.Y.;Ahn, S.H.;Seto, W.K.;Ning, Q.;Agarwal, K.;Janssen, H.L.A.;Pan, C.Q.;Chuang, W.L.;Izumi, N.;Fung, S.;Shalimar;Brunetto, M.;Hui, A.J.;Chang, T.-T.;Lim, S.G.;Abramov, F.;Flaherty, J.F.;Wang, H.;Yee, L.J.;Kao, J.-H.;Gane, E.;Hou, J.;Buti, M. |
| 臺大學術典藏 |
2021-09-04T06:11:33Z |
Reimbursement policies in the Asia-Pacific for chronic hepatitis B
|
Lim S.G.; Amarapurkar D.N.; Chan H.L.-Y.; Crawford D.H.; Gane E.J.; Han K.-H.; Ahn S.H.; Jafri W.; Jia J.; JIA-HORNG KAO; Lesmana L.A.; Lesmana C.R.A.; Mohamed R.; Phiet P.H.; Piratvisuth T.; Sarin S.K.; Sollarno J.D.; Eguchi Y.; Mahtab M.-A.; Lee K.H. |
| 臺大學術典藏 |
2021-09-04T06:11:11Z |
All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study
|
JIA-HORNG KAO; Lee Y.-J.; Heo J.; Ahn S.-H.; Lim Y.-S.; Peng C.-Y.; Chang T.-T.; Torbeyns A.; Hughes E.; Bhore R.; Noviello S. |
| 臺大學術典藏 |
2021-09-04T06:11:02Z |
Urgency to treat patients with chronic hepatitis C in Asia
|
JIA-HORNG KAO; Ahn S.H.; Chien R.-N.; Cho M.; Chuang W.-L.; Jeong S.-H.; Liu C.-H.; Paik S.-W. |
| 臺大學術典藏 |
2021-09-04T05:17:13Z |
Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1
|
JIA-HORNG KAO; Yu M.-L.; Peng C.-Y.; Heo J.; Chu C.-J.; Chang T.-T.; Lee Y.-J.; Hu T.-H.; Yoon K.T.; Paik S.W.; Lim Y.S.; Ahn S.H.; Isakov V.; McPhee F.; Hu W.; Scott Swenson E.; Yin P.D.; Treitel M. |
| 臺大學術典藏 |
2021-09-04T05:17:06Z |
The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C
|
Younossi Z.M.; Stepanova M.; Henry L.; Han K.-H.; Ahn S.H.; Lim Y.-S.; Chuang W.-L.; JIA-HORNG KAO; Kinh N.; Lai C.L.; Yuen M.-F.; Chan H.L.-Y.; Lai W. |
| 臺大學術典藏 |
2021-09-04T05:17:00Z |
Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection
|
Younossi Z.M.; Stepanova M.; Henry L.; Han K.-H.; Ahn S.H.; Lim Y.-S.; Chuang W.-L.; JIA-HORNG KAO; Nguyen K.V.; Lai C.L.; Chan H.L.-Y.; Wei L. |
| 臺大學術典藏 |
2021-09-04T05:16:25Z |
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
|
Eslam M.; Sarin S.K.; Wong V.W.-S.; Fan J.-G.; Kawaguchi T.; Ahn S.H.; Zheng M.-H.; Shiha G.; Yilmaz Y.; Gani R.; Alam S.; Dan Y.Y.; JIA-HORNG KAO; Hamid S.; Cua I.H.; Chan W.-K.; Payawal D.; Tan S.-S.; Tanwandee T.; Adams L.A.; Kumar M.; Omata M.; George J. |
| 臺大學術典藏 |
2021-07-03T03:34:47Z |
Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions
|
Ahn S.H.; Chan H.L.Y.; PEI-JER CHEN; Cheng J.; Goenka M.K.; Hou J.; Lim S.G.; Omata M.; Piratvisuth T.; Xie Q.; Yim H.J.; Yuen M.-F. |
| 臺大學術典藏 |
2021-07-03T03:34:37Z |
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score
|
Yang H.-I.; Yuen M.-F.; Chan H.L.Y.; Han K.-H.; PEI-JER CHEN; Kim D.-Y.; Ahn S.-H.; Chen C.-J.; Wong V.W.S.; Seto W.-K. |
